Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Francesca PalandriElena Maria ElliErika MorsiaGiulia BenevoloMario TiribelliEloise BeggiatoMassimiliano BonifacioMirko FarinaBruno MartinoGiovanni CaocciNovella PuglieseAlessia TieghiMonica CrugnolaGianni BinottoFrancesco CavazziniElisabetta AbruzzeseAlessandra IurloAlessandro IsidoriCostanza BosiVeronica GuglielmanaMarta VenturiAlessandra DedolaMichele LoffredoGabriele FontanaAndrea DuminucoAlessia MoioliLuca TosoniEmilia ScalzulliDaniele CattaneoRoberto M LemoliDaniela CilloniMonica BocchiaFabrizio PaneFlorian H HeidelNicola VianelliMichele CavoGiuseppe A PalumboFilippo BranzantiMassimo BrecciaPublished in: Cancer (2024)
In INT1 patients, responses were more frequent and durable, whereas toxicity rates were lower compared to INT2/high-risk patients. Presence of HMR mutations, cytopenia, and peripheral blasts identified less-responsive INT1 patients, who may benefit for alternative therapeutic strategies.